Loading...
Loading...
- Hims & Hers Health Inc HIMS reported fourth-quarter FY21 sales growth of 104% year-on-year, to $84.7 million, beating the consensus of $76.79 million.
- The average order value for the quarter was $74. Q4 2021 ending member subscriptions grew 95% year-over-year to 609,000.
- The gross profit margin contracted 400 basis points Y/Y to 73%, and the gross profit rose 94.7% Y/Y to $62.1 million.
- The loss from operations widened to $(21.6) million.
- The company held $247 million in cash and equivalents as of December 31, 2021.
- EPS of $(0.15) missed the analyst consensus of $(0.07).
- The adjusted EBITDA loss widened to $(7.1) million.
- Outlook: Hims & Hers sees Q1 sales of $90 million - $93 million versus the consensus of $77.92 million.
- The company expects FY22 sales of $365 million - $380 million against the consensus of $350.75 million.
- Price Action: HIMS shares are trading higher by 14.5% at $4.78 in premarket on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in